Apr 11 |
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
|
Apr 4 |
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
|
Mar 18 |
Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment
|
Mar 18 |
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
Mar 12 |
Sidoti Events, LLC's Virtual March Small-Cap Conference
|
Mar 7 |
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
|
Feb 26 |
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
|
Feb 23 |
Citius Pharmaceuticals files for $250M mixed securities shelf
|
Feb 23 |
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
|
Feb 14 |
Citius Pharmaceuticals GAAP EPS of -$0.06
|